巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Tonix Pharmaceuticals Holding Corp

    TNXP
    2.060
    0.080
    3.78%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Tonix Pharmaceuticals Holding Corp - 延遲價格・最後更新於 26/05 12:14
    最高位
    2.105
    最低位
    1.920
    開市價
    --
    前收市價
    1.985
    成交量(千)
    57.09
    成交額(百萬)
    0.93
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    38.60
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    45.440 - 1.910
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Tonix Pharmaceuticals Holding Corp
    證券代碼
    TNXP.US
    所屬板塊
    Biotechnology
    公司業務
    Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.
    發行量
    533928624
    公司總部
    26 Main Street, Suite 101
    公司網址
    https://www.tonixpharma.com
    公司電郵
    investor.relations@tonixpharma.com
    公司電話
    +1 862 799-8599

    美股“猴痘概念股”繼續走強

    格隆匯··精選
    美股“猴痘概念股”繼續走強

    美股“猴痘概念股”繼續走強

    格隆匯·
    美股“猴痘概念股”繼續走強

    關於

    Tonix Pharmaceuticals Holding Corp(TNXP.US)所屬的行業板塊為Biotechnology。
    Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.
    詳細公司背景可參考: https://www.tonixpharma.com